Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Gyre Therapeutics (GYRE) Net Income towards Common Stockholders: 2009-2024

Historic Net Income towards Common Stockholders for Gyre Therapeutics (GYRE) over the last 16 years, with Dec 2024 value amounting to $12.1 million.

  • Gyre Therapeutics' Net Income towards Common Stockholders rose 221.17% to $3.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.7 million, marking a year-over-year increase of 107.49%. This contributed to the annual value of $12.1 million for FY2024, which is 113.00% up from last year.
  • Gyre Therapeutics' Net Income towards Common Stockholders amounted to $12.1 million in FY2024, which was up 113.00% from -$92.9 million recorded in FY2023.
  • Over the past 5 years, Gyre Therapeutics' Net Income towards Common Stockholders peaked at $12.1 million during FY2024, and registered a low of -$92.9 million during FY2023.
  • In the last 3 years, Gyre Therapeutics' Net Income towards Common Stockholders had a median value of $2.3 million in 2022 and averaged -$26.2 million.
  • Per our database at Business Quant, Gyre Therapeutics' Net Income towards Common Stockholders plummeted by 4,137.05% in 2023 and then surged by 113.00% in 2024.
  • Gyre Therapeutics' Net Income towards Common Stockholders (Yearly) stood at -$56.2 million in 2020, then tumbled by 56.35% to -$87.9 million in 2021, then soared by 102.62% to $2.3 million in 2022, then tumbled by 4,137.05% to -$92.9 million in 2023, then skyrocketed by 113.00% to $12.1 million in 2024.